Highlights Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
8.97 ^USD	-6.07%		-5.28%	+12.69%

04-24	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	MT
04-24	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	04-24	MT
Centessa Pharmaceuticals plc Announces Open IND for ORX750	04-22	CI
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Centessa Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia	12-10	CI
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	11-27	MT
Anaptysbio, Inc. Enters into License Agreement with Centessa Pharmaceuticals (UK) Limited	11-27	CI
Centessa Pharmaceuticals' Q3 Loss Narrows	11-13	MT
Centessa Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors	31/10/23	CI
Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders	25/10/23	CI
World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc	24/08/23	CI
Centessa Pharmaceuticals plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B Without Inhibitors	10/07/23	CI
Centessa Pharmaceuticals Says US FDA Granted Fast Track Designation for Potential Hemophilia B Treatment	22/05/23	MT
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for Serpinpc for Hemophilia B	22/05/23	CI
Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Centessa Pharmaceuticals' Q4 Net Loss Narrows	30/03/23	MT
CENTESSA PHARMACEUTICALS PLC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	30/03/23	AQ
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Highlights

Filters